Therapeutic potential of PDE modulation in treating heart disease

Future Medicinal Chemistry

Volumn 5, Issue 14, 2013, Pages 1607-1620

  Knight, Walter ^a   Yan, Chen ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; AMRINONE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENOXIMONE; IC 86340; MILRINONE; PF 04957325; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VIII; ROFLUMILAST; ROLIPRAM; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VINPOCETINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FIBROBLAST; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; SECOND MESSENGER; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; CYCLIC GMP; DRUG DISCOVERY; HEART DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 84884559109     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.127     Document Type: Review

References (102)

1. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325(21), 1468-1475 (1991).
2. Guazzi M, Vicenzi M, Arena R, Guazzi MD: PDE5 Inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure/clinical perspective. Circ. Heart Fail. 4(1), 8-17 (2011).
3. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ. Res. 93(10), 896-906 (2003).
4. Halls ML, Cooper DM. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex. EMBO J. 29(16), 2772-2787 (2010).
5. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 58(3), 488-520 (2006).
6. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 109(3), 366-398 (2006).
7. Miller CL, Yan C. Targeting cyclic nucleotide phosphodiesterase in the heart: Therapeutic implications. J. Cardiovasc. Transl. Res. 3(5), 507-515 (2010).
8. Vandeput F, Wolda SL, Krall J et al. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J. Biol. Chem. 282(45), 32749-32757 (2007).
9. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 83(5A), 3C-12C (1999).
10. Miller CL, Oikawa M, Cai Y et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ. Res. 105(10), 956-964 (2009).
11. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc. Natl Acad. Sci. USA 107(12), 5646-5651 (2010).
12. Miller CL, Cai Y, Oikawa M et al. Cyclic nucleotide phosphodiesterase 1A: A key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Res. Cardiol. 106(6), 1023-1039 (2011).
13. Vandeput F, Krall J, Ockaili R et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J. Pharmacol. Exp. Ther. 330(3), 884-891 (2009).
14. Mongillo M, Tocchetti CG, Terrin A et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ. Res. 98(2), 226-234 (2006).
15. Dittrich M, Jurevicius J, Georget M et al. Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes. J. Physiol. 534(Pt 1), 109-121 (2001).
16. Rivet-Bastide M, Vandecasteele G, Hatem S et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J. Clin. Invest. 99(11), 2710-2718 (1997).
17. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 142(2), 136-143 (2005).
18. Mery PF, Lohmann SM, Walter U, Fischmeister R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl Acad. Sci. USA 88(4), 1197-1201 (1991).
19. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113(18), 2221-2228 (2006).
20. Yanaka N, Kurosawa Y, Minami K, Kawai E, Omori K. cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles. Biosci. Biotechnol. Biochem. 67(5), 973-979 (2003).
21. Aye T-T, Soni S, Van Veen TaB et al. Reorganized PKA-AKAP associations in the failing human heart. J. Mol. Cell. Cardiol. 52(2), 511-518 (2012).
22. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. 272(11), 6823-6826 (1997).
23. Brown C, Pan X, Hassid A. Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: Relationship to microfilament dissociation and altered cell morphology. Circ. Res. 84(6), 655-667. (1999).
24. Osinski MT, Rauch BH, Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol. Pharmacol. 59(5), 1044-1050. (2001).
25. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ. Res. 93(5), 406-413 (2003).
26. Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3), 238-248 (2007).
27. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125(7), 1501-1510 (1998).
28. Knight WE, Yan C. Cardiac cyclic nucleotide phosphodiesterases: Function, regulation, and therapeutic prospects. Horm. Metab. Res. 44(10), 766-775 (2012).
29. Beca S, Aschars-Sobbi R, Panama BK, Backx PH. Regulation of murine cardiac function by phosphodiesterases type 3 and 4. Curr. Opin. Pharmacol. 11(6), 714-719 (2011).
30. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J. Clin. Invest. 75(2), 643-649 (1985).
31. Sun B, Li H, Shakur Y et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell. Signal. 19(8), 1765-1771 (2007).
32. Vinogradova TM, Sirenko S, Lyashkov AE et al. Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Circ. Res. 102(7), 761-769 (2008).
33. Beca S, Ahmad F, Shen W et al. PDE3A regulates basal myocardial contractility through interacting with SERCA2a-signaling complexes in mouse heart. Circ. Res. 112(2), 289-297 (2013).
34. Damilano F, Perino A, Hirsch E. PI3K kinase and scaffold functions in heart. Ann. NY Acad. Sci. 1188, 39-45 (2010).
35. Patrucco E, Notte A, Barberis L et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118(3), 375-387 (2004).
36. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281(15), 9977-9986 (2006).
37. Perino A, Ghigo A, Ferrero E et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol. Cell 42(1), 84-95 (2011).
38. Marcantoni A, Levi RC, Gallo MP, Hirsch E, Alloatti G. Phosphoinositide 3-kinasegamma (PI3Kgamma) controls L-type calcium current (ICa,L) through its positive modulation of type-3 phosphodiesterase (PDE3). J. Cell. Physiol. 206(2), 329-336 (2006).
39. Kerfant B-G, Zhao D, Lorenzen-Schmidt I et al. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ. Res. 101(4), 400-408 (2007).
40. Ghigo A, Perino A, Mehel H et al. Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 126(17), 2073-2083 (2012).
41. Baim DS, Mcdowell AV, Cherniles J et al. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N. Engl. J. Med. 309(13), 748-756 (1983).
42. Packer M. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am. J. Cardiol. 63(2), 41A-45A (1989).
43. Assad-Kottner C, Chen D, Jahanyar J et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. J. Cardiac Fail. 14(10), 839-843 (2008).
44. Cuffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure a randomized controlled trial. JAMA 287(12), 1541-1547 (2002).
45. Ding B, Abe J, Wei H et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure. Circulation 111(19), 2469-2476 (2005).
46. Ding B, Abe J, Wei H et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc. Natl Acad. Sci. USA 102(41), 14771-14776 (2005).
47. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ. Res. 100(4), 489-501 (2007).
48. Smith CJ, He J, Ricketts SG, Ding JZ, Moggio RA, Hintze TH. Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. Cell Biochem. Biophys. 29(1-2), 67-88 (1998).
49. Yan C, Ding B, Shishido T et al. Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ. Res. 100(4), 510-519 (2007).
50. Ma D, Fu L, Shen J et al. Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction. Eur. J. Pharmacol. 602(2-3), 348-354 (2009).
51. Abi-Gerges A, Richter W, Lefebvre F et al. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ. Res. 105(8), 784-792 (2009).
52. Beca S, Ahmad F, Shen W et al. PDE3A regulates basal myocardial contractility through interacting with SERCA2a-signaling complexes in mouse heart. Circ. Res. 112(2), 289-297 (2013).
53. Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello VC. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J. Biol. Chem. 275(16), 12331-12338. (2000).
54. Kostic MM, Erdogan S, Rena G et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin- preconditioned rat heart. J. Mol. Cell. Cardiol. 29(11), 3135-3146 (1997).
55. Leroy JRM, Richter W, Mika D et al. Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice. J. Clin. Invest. 121(7), 2651-2661 (2011).
56. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res. Cardiol. 106(2), 249-262 (2011).
57. De Arcangelis V, Liu R, Soto D, Xiang Y. Differential association of phosphodiesterase 4D isoforms with beta2-adrenoceptor in cardiac myocytes. J. Biol. Chem. 284(49), 33824-33832 (2009).
58. Baillie GS, Sood A, Mcphee I et al. Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc. Natl Acad. Sci. USA 100(3), 940-945 (2003).
59. Richter W, Day P, Agrawal R et al. Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 27(2), 384-393 (2008).
60. Berthouze-Duquesnes M, Lucas A, Sauliere A et al. Specific interactions between Epac1, beta-arrestin2 and PDE4D5 regulate beta-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling. Cell Signal. 25(4), 970-980 (2013).
61. Lehnart SE, Wehrens XHT, Reiken S et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123(1), 25-35 (2005).
62. Galindo-Tovar A, Kaumann AJ. Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors. Br. J. Pharmacol. 153(4), 710-720 (2008).
63. Beca S, Helli PB, Simpson JA et al. Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current. Circ. Res. 109(9), 1024-1030 (2011).
64. Molina CE, Leroy JRM, Richter W et al. Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. J. Am. Coll. Cardiol. 59(24), 2182-2190 (2012).
65. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 374(9691), 685-694 (2009).
66. Kranz M, Wall M, Evans B et al. Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg. Med. Chem. 17(14), 5336-5341 (2009).
67. Kotera J, Fujishige K, Imai Y et al. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur. J. Biochem. 262(3), 866-873 (1999).
68. Corbin J, Rannels S, Neal D et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr. Med. Res. Opin. 19(8), 747-752 (2003).
69. Pokreisz P, Vandenwijngaert S, Bito V et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119(3), 408-416 (2009).
70. Zhang M, Koitabashi N, Nagayama T et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal. 20(12), 2231-2236 (2008).
71. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112(17), 2642-2649 (2005).
72. Takimoto E, Belardi D, Tocchetti CG et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115(16), 2159-2167 (2007).
73. Takimoto E, Champion HC, Belardi D et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ. Res. 96(1), 100-109 (2005).
74. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 75(2), 303-314 (2007).
75. Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3), 238-248 (2007).
76. Lu Z, Xu X, Hu X et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121(13), 1474-1483 (2010).
77. Vandenwijngaert S, Pokreisz P, Hermans H et al. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PLoS ONE 8(3), e58841 (2013).
78. Zhang M, Takimoto E, Lee DI et al. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation 126(8), 942-951 (2012).
79. Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11(2), 214-222 (2005).
80. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. 92(6), 595-597 (2003).
81. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. Heart Circ. Physiol. 283(3), H1263-H1269 (2002).
82. Westermann D, Becher PM, Lindner D et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res. Cardiol. 107(6), 308 (2012).
83. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111(13), 1601-1610 (2005).
84. Nishida M, Watanabe K, Sato Y et al. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J. Biol. Chem. 285(17), 13244-13253 (2010).
85. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem. 280(13), 12944-12955 (2005).
86. Takimoto E, Koitabashi N, Hsu S et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119(2), 408-420 (2009).
87. Chakir K, Zhu W, Tsang S et al. RGS2 is a primary terminator of [beta]2-adrenergic receptor-mediated Gi signaling. J. Mol. Cell. Cardiol. 50(6), 1000-1007 (2011).
88. Koitabashi N, Aiba T, Hesketh GG et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation novel mechanism of cardiac stress modulation by PDE5 inhibition. J. Mol. Cell. Cardiol. 48(4), 713-724 (2010).
89. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am. J. Physiol. Heart Circ. Physiol. 300(6), H2272-H2279 (2011).
90. Frantz S, Klaiber M, Baba HA et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur. Heart J. 34(16), 1233-1244 (2011).
91. Nagayama T, Hsu S, Zhang M et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J. Mol. Cell. Cardiol. 46(4), 560-567 (2009).
92. Salloum FN, Chau VQ, Hoke NN et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 120(11 Suppl. 1), S31-S36 (2009).
93. Zhang M, Takimoto E, Hsu S et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J. Am. Coll. Cardiol. 56(24), 2021-2030 (2010).
94. Kass DA. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: From experimental models to clinical trials. Curr. Heart Fail. Rep. 9(3), 192-199 (2012).
95. Redfield MM, Borlaug BA, Lewis GD et al. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: Rationale and design. Circ. Heart Fail. 5(5), 653-659 (2012).
96. Giannetta E, Isidori AM, Galea N et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: A randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125(19), 2323-2333 (2012).
97. Reichenbach A, Al-Hiti H, Malek I et al. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.09.074 (2012) (Epub ahead of print).
98. Goldberg DJ, French B, Szwast AL et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr. Cardiol. 33(5), 689-696 (2012).
99. Redfield MM, Chen HH, Borlaug BA et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 309(12), 1268-1277 (2013).
100. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl Acad. Sci. USA 95(15), 8991-8996. (1998).
101. Patrucco E, Albergine MS, Santana LF, Beavo JA. Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J. Mol. Cell. Cardiol. 49(2), 330-333 (2010).
102. Cygnar KD, Zhao H. Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons. Nat. Neurosci. 12(4), 454-462 (2009).